ReviewCNS neuroscience & therapeutics2010
Relevance of norepinephrine-dopamine interactions in the treatment of major depressive disorder.
Review in CNS neuroscience & therapeutics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed.
- Reproductive steroid receptors and actions in the locus coeruleus of male macaques: Part of an aggression circuit?Progress in neuro-psychopharmacology & biological psychiatry · 2016Trial
- Effects of levomilnacipran extended-release on motivation/energy and functioning in adults with major depressive disorder.International clinical psychopharmacology · 2016Trial
- Erotic stimulus processing under amisulpride and reboxetine: a placebo-controlled fMRI study in healthy subjects.The international journal of neuropsychopharmacology · 2014Trial
- The Pupil-Brain System at Rest: Spontaneous Pupil Fluctuations as Markers of Neuromodulatory and Network Dynamics.Psychophysiology · 2026Review
- From Stress to Neurodegeneration: A New Look at the Pathogenesis of Parkinson's Disease.Biomedicines · 2026Review
- Association between the combination of GABAergic agents and SSRIs at the first clinical visit and depressive symptom trajectories: A study using group-based trajectory modeling and Apriori algorithm.PLOS mental health · 2026Article
- Neurobiological Mechanisms of Electroconvulsive Therapy: Molecular Perspectives of Brain Stimulation.International journal of molecular sciences · 2025Review
- Monoamine-Uptake Inhibitors and Pain: Antidepressant Drugs Among First-Line Treatments Against Neuropathic Pain and Fibromyalgia.Advances in neurobiology · 2025Review
- State-dependent memory mechanisms insights from neural circuits and clinical implications.Frontiers in cellular neuroscience · 2025Review
- Unraveling the complexities of adolescent depression: A call for action.World journal of psychiatry · 2024Article
- The Formation and Function of the VTA Dopamine System.International journal of molecular sciences · 2024Review
- Editorial: New players on the monoaminergic field: relevance to the mental disorders.Frontiers in pharmacology · 2024Article
- Review
- Effects of Combining Music Therapy, Light Therapy, and Chromotherapy in the Treatment of Chronic Pain Patients: A Pilot Study.Evidence-based complementary and alternative medicine : eCAM · 2024Article
- The Associations of Vitamin D with Ovarian Reserve Markers and Depression: A Narrative Literature Review.Nutrients · 2023Review
- Neuronal activity in the human amygdala and hippocampus enhances emotional memory encoding.Nature human behaviour · 2023Article
- Serotonergic mediation of the brain-wide neurogenesis: Region-dependent and receptor-type specific roles on neurogenic cellular transformation.Current research in neurobiology · 2023Review
- The role of Neurochemicals, Stress Hormones and Immune System in the Positive Feedback Loops between Diabetes, Obesity and Depression.Frontiers in endocrinology · 2023Review
- Therapeutic potential of plant iridoids in depression: a review.Pharmaceutical biology · 2022Review
- Effects of Atomoxetine on Motor and Cognitive Behaviors and Brain Electrophysiological Activity of Dopamine Transporter Knockout Rats.Biomolecules · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Central dopaminergic and noradrenergic systems play essential roles in controlling several forebrain functions. Consequently, perturbations of these neurotransmissions may contribute to the pathophysiology of neuropsychiatric disorders. For many years, there was a focus on the serotonin (5-HT) system because of the efficacy of selective serotonin reuptake inhibitors (SSRIs), the most prescribed antidepressants in the treatment of major depressive disorder (MDD). Given the interconnectivity within the monoaminergic network, any action on one system may reverberate in the other systems. Analysis of this network and its dysfunctions suggests that drugs with selective or multiple modes of action on dopamine (DA) and norepinephrine (NE) may have robust therapeutic effects. This review focuses on NE-DA interactions as demonstrated in electrophysiological and neurochemical studies, as well as on the mechanisms of action of agents with either selective or dual actions on DA and NE. Understanding the mode of action of drugs targeting these catecholaminergic neurotransmitters can improve their utilization in monotherapy and in combination with other compounds particularly the SSRIs. The elucidation of such relationships can help design new treatment strategies for MDD, especially treatment-resistant depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.